New York, US (PRWEB) August 20, 2014
Understanding the impact of clinical, patient advocate, market access, governmental and physician stakeholders networks impacting the launch of new melaoma products in Europe, Asia-Pacific, Latin America, US, Canada, and Emerging Markets.
This Flash Report is a top-line view into Heartbeat Experts’ perspectives on stakeholder management needs for the melanoma market.
ASCO 2014 highlighted several new immunotherapy and targeted therapy investigational agents that are further improving median survival rates in late-stage melanoma. These new agents, including monoclonal PD-1 antibodies and BRAF inhibitors, may quickly change the treatment options available for melanoma cancer specialists. It is paramount that companies that compete in this market sector are fully engaged with the leading investigators and key opinion leaders who are affecting the adoption of these emerging treatments by key stakeholders. It is also paramount that companies consider the cost and market access implications of these treatments and understand the pool of stakeholders who will be central in discussions and decisions driving access for these molecules.
Heartbeat Experts serves 35 of the top 35 pharmaceutical companies on addressing these stakeholder management challenges for across North America, Latin America, Europe, Asia-Pacific, and the Middle East.
Please contact one of our regional headquarters below to schedule an in depth discussion of our solution to the challenges outlined in this Flash Report.
About Heartbeat Experts:
Heartbeat Experts is the leading stakeholder management solution provider serving 20 of the top 20 pharmaceutical companies and 18 of the top 20 medical device companies. Heartbeat Experts provides software and data for KOL identification, KOL management, pricing and reimbursement, formulary access, regulatory affairs, a suite of stakeholder engagement products including virtual advisory boards, HCP communities and market research.